Pulmonary Arterial Hypertension Market Dynamics, Drug Pipeline, and Demand Forecast By 2031 | Most Leading Companies - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company

The Global Pulmonary Arterial Hypertension Market size was worth USD 7 billion in 2022 and is estimated to reach USD 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2024-2031.

Pulmonary Arterial Hypertension Market Report by DataM Intelligence delivers deep insights and analysis into the latest market trends, growth opportunities, and emerging challenges. Designed to help businesses make smarter, faster decisions, our reports combine both data-driven analysis and expert perspectives. At DataM Intelligence, we're committed to turning complex market landscapes into clear, actionable strategies so you can stay competitive, grow confidently, and seize the right opportunities in a rapidly changing world.

Unlock exclusive insights with our detailed sample report (Please enter your Corporate Email ID to get priority access): https://datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market?kb

The Pulmonary Arterial Hypertension market refers to the global industry focused on the research, development, production, and commercialization of treatments for PAH-a rare, progressive disorder characterized by high blood pressure in the arteries of the lungs. The market includes drugs, diagnostic tools, and therapeutic devices aimed at improving patient outcomes and quality of life.

List of the Key Players in the Pulmonary Arterial Hypertension Market:

Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation

Industry Development:

In May 2023, the Institute for Clinical and Economic Review (ICER) announced its evaluation of sotatercept, a groundbreaking first-in-class therapy developed for pulmonary arterial hypertension (PAH). This review aims to assess the drug's clinical benefits and its overall value in the healthcare system. Sotatercept works by blocking abnormal signaling pathways in pulmonary blood vessels, particularly those involving growth mediators like activins. By restoring the balance between growth-promoting and inhibitory signals, it addresses the underlying cause of PAH namely, the narrowing of small pulmonary arteries that restricts blood flow from the heart to the lungs.

Also in May 2023, Gossamer Bio shared plans to initiate a Phase 3 clinical trial for seralutinib (GB002), its inhaled therapy candidate for PAH. The company confirmed its readiness to move forward with the trial in the coming months, marking a critical step toward potentially bringing a novel treatment option to patients suffering from this progressive and life-threatening condition.

Meanwhile, in April 2023, the U.S. Food and Drug Administration (USFDA) approved a generic version of Treprostinil injectable, manufactured by Dr. Reddy's Laboratories, as a therapeutic equivalent to Remodulin. Available in multiple strengths - 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml, and 200 mg/20 ml the injectable is a prostacyclin analog designed to help slow clinical worsening in PAH patients, particularly those transitioning from epoprostenol therapy.

Research Process:

Both primary and secondary data sources have been used in the global Pulmonary Arterial Hypertension Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/pulmonary-arterial-hypertension-market?kb

Segment Covered in the Pulmonary Arterial Hypertension Market:

By Drug Class: Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and Others)

By Route of Administration: Inhalation, Injectable and Oral Administration

By Distribution channel: Hospital Pharmacy, Pharmacy stores, and Others

Regional Analysis for Pulmonary Arterial Hypertension Market:

The regional analysis of the Pulmonary Arterial Hypertension Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pulmonary-arterial-hypertension-market?kb

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Pulmonary Arterial Hypertension market?

➠ Who are the leading manufacturers in the global Pulmonary Arterial Hypertension industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Pulmonary Arterial Hypertension industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Pulmonary Arterial Hypertension market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.